III/IV期随机对照试验中患者与公众参与及最小临床重要差异的报告情况:一项系统综述
该研究检索了Medline、Embase和Cochrane对照试验中心注册库,纳入2019年7月1日至2020年1月13日间发表的123项III/IV期随机对照试验,评估患者与公众参与(PPI)及最小临床重要差异(MCID)的报告情况。结果显示仅2.4%(n=3)和1.6%(n=2)的试验分别描述了PPI和MCID,作者认为报告情况不佳,改善报告可增加结果对患者相关性和临床显著性的信心。
要点
- 123项III/IV期随机对照试验中仅2.4%(n=3)报告了患者与公众参与(PPI)。
- 仅1.6%(n=2)报告了最小临床重要差异(MCID)。
- 作者认为PPI和MCID报告不佳,改善报告可提升试验设计质量。
核心结论
- PPI和MCID的报告情况不佳,因此不确定它们如何影响试验设计。
- 改善这些条目的报告将增加结果对患者具有相关性和临床显著性的信心,有助于改善整体试验设计。
研究设计与样本
- 系统综述,检索Medline、Embase和Cochrane对照试验中心注册库。
- 纳入英文发表的III/IV期随机对照试验主要出版物,涵盖任何医学专科或干预类型,报告健康相关结局。
- 排除试验方案和随机对照试验的二次发表。
- 共纳入2019年7月1日至2020年1月13日间匹配标准的123项III/IV期随机对照试验。
- 提取试验特征、PPI使用情况和MCID使用情况。
主要发现
- 90%的试验评估药物而非手术干预。
- 肿瘤学占所有纳入随机对照试验的21%。
- 仅2.4%(n=3)的随机对照试验描述了PPI。
- 仅1.6%(n=2)的随机对照试验描述了MCID。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient and public involvement (PPI) in clinical trial design contributes to ensuring the research objectives and outcome measures are relevant to patients. The minimal clinically important difference (MCID) in the primary outcome influences trial design and feasibility and should be predicated on PPI. We aimed to determine current practice of reporting PPI and the MCID in phase III/IV randomised controlled trials (RCTs). METHODS: Following a search of Medline, Embase, and the Cochrane Central Register of Controlled Trials, we included primary publications of phase III/IV RCTs, in English, inclusive of any medical specialty or type of intervention, that reported a health-related outcome. We excluded protocols and secondary publications of RCTs. We extracted RCT characteristics, the use of PPI, and use of the MCID. RESULTS: Between 1 July 2019 and 13 January 2020, 123 phase III/IV RCTs matched our eligibility criteria. Ninety percent evaluated a medical rather than surgical intervention. Oncology accounted for 21% of all included RCTs. Only 2.4% (n = 3) and 1.6% (n = 2) RCTs described PPI and the MCID respectively. CONCLUSIONS: PPI and the MCID are poorly reported, so it is uncertain how these contributed to trial design. Improvement in the reporting of these items would increase confidence that results are relevant and clinically significant to patients, contributing to improving the overall trial design. TRIAL REGISTRATION: Not registered.
引用
- Brennan J, Poon MTC, Christopher E, et al. Reporting of PPI and the MCID in phase III/IV randomised controlled trials-a systematic review. Trials. 2023. PMID: 37259102. doi:10.1186/s13063-023-07367-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。